Abstract:Antimicrobial resistance is an increasing global threat, demanding new therapeutic biomolecules against multidrug-resistant bacteria. Antimicrobial peptides (AMPs) are promising candidates for a new generation of antibiotics, but their potential application is still in its infancy, mostly due to limitations associated with large-scale production. The use of recombinant DNA technology for the production of AMPs fused with polymer tags presents the advantage of high-yield production and cost-efficient purification processes at high recovery rates. Owing to their unique properties, we explored the use of an elastin-like recombinamer (ELR) as a fusion partner for the production and isolation of two different AMPs (ABP-CM4 and Synoeca-MP), with an interspacing formic acid cleavage site. Recombinant AMP-ELR proteins were overproduced in Escherichia coli and efficiently purified by temperature cycles. The introduction of a formic acid cleavage site allowed the isolation of AMPs, resorting to a two-step methodology involving temperature cycles and a simple size-exclusion purification step. This simple and easy-to-implement purification method was demonstrated to result in high recovery rates of bioactive AMPs. The minimum inhibitory concentration (MIC) of the free AMPs was determined against seven different bacteria of clinical relevance (Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and two Burkholderia cenocepacia strains), in accordance with the EUCAST/CLSI antimicrobial susceptibility testing standards. All the bacterial strains (except for Pseudomonas aeruginosa) were demonstrated to be susceptible to ABP-CM4, including a resistant Burkholderia cenocepacia clinical strain. As for Synoeca-MP, although it did not inhibit the growth of Pseudomonas aeruginosa or Klebsiella pneumoniae, it was demonstrated to be highly active against the remaining bacteria. The present work provides the basis for the development of an efficient and up-scalable biotechnological platform for the production and purification of active AMPs against clinically relevant bacteria.

Functional Production of Catalytic Domains of Human MMPs in Escherichia coli Periplasm

Direct production of functional matrix metalloproteinase--14 without refolding or activation and its application for in vitro inhibition assays

MMP Enzyme in Tumor Micro-environment: A Promising Target for Nano-medicine Delivery

Expression, purification and refolding of pro-MMP-2 from inclusion bodies of E. coli

Over-expression and Refolding of Isotopically Labeled Recombinant Catalytic Domain of Human Macrophage Elastase (MMP-12) for NMR Studies.

A DNA-directed covalent conjugation fluorescence probe for in vitro detection of functional matrix metalloproteinases.

The efficient expression of human fibroblast collagenase in Escherichia coli and the discovery of flavonoid inhibitors

Dual Inhibitory Pathways of Metallofullerenol Gd@C82(OH)22 on Matrix Metalloproteinase-2: Molecular Insight into Drug-Like Nanomedicine

Identification of collagen binding domain residues that govern catalytic activities of matrix metalloproteinase-2 (MMP-2)

Expression in Escherichia coli, refolding, and purification of the recombinant mature form of human matrix metalloproteinase 7 (MMP-7)

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics

Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme

The Structural Biology and Critical Evaluation of Bacterial Proteases as Targets in New Drug Design

Structural Studies of Matrix Metalloproteinase by X-Ray Diffraction

Development of a high yielding E. coli periplasmic expression system for the production of humanized Fab' fragments

Analysis of Matrix Metalloproteinase Triple-Helical Peptidase Activity with Substrates Incorporating Fluorogenic L- or D-amino Acids.

Functional expression of diverse post-translational peptide-modifying enzymes in Escherichia coli under uniform expression and purification conditions

Design and production of a novel antimicrobial fusion protein in Escherichia coli

Bioproduction Platform to Generate Functionalized Disulfide-Constrained Peptide Analogues

Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase

Production and Purification of Two Bioactive Antimicrobial Peptides Using a Two-Step Approach Involving an Elastin-Like Fusion Tag